Walter Taal

Lomustine and Bevacizumab in Progressive Glioblastoma

Wolfgang Wick, Thierry Gorlia, Martin Bendszus et al. · New England Journal of Medicine · 2017 · 978 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek Walenkamp et al. · The Lancet Oncology · 2014 · 753 citations

Medicine, Oncology, Pharmacotherapy +16

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

Walter Taal, Dieta Brandsma, Hein G. de Bruin et al. · Cancer · 2008 · 464 citations · Full text

Medicine, Oncology, Radiation Oncology +10

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent, Brigitta G. Baumert, Sara Erridge et al. · The Lancet · 2017 · 397 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 327 citations · Full text

Medicine, Oncology, Pharmacology +16